IQVIA Holdings (IQV) came out with quarterly earnings of $2.64 per share, beating the Zacks Consensus Estimate of $2.58 per share. This compares to earnings of $2.43 per share a year ago.
Contract research firm IQVIA Holdings raised its forecast for full-year profit on Monday, banking on strength in demand for its healthcare data and analytics services.
IQVIA's (IQV) second-quarter 2024 revenues are likely to have gained from growth in the Technology and Analytics, and Research and Development segments.
IQVIA (IQV) benefits from its healthcare-specific global IT infrastructure and domain expertise to expand and penetrate different markets.
IQVIA's (IQV) One Home for Sites allows pharmaceutical companies and their software vendors to streamline clinical application management.
There have been numerous positive updates to IQVIA Holdings' fundamental economics since January 2023. It produced strong Q1 2024 earnings, with growth observed in all segments. Increasing returns from margin growth and capital productivity are driving exceptional free cash flow production.
IQVIA (IQV) benefits from a powerful healthcare-specific global IT infrastructure and a robust real-world solutions ecosystem. However, high operating expenses are a headwind.